HUMIRA and Crohn’s Disease

HUMIRA has been proven to induce and maintain remission (little or no symptoms) in many people with moderate to severe Crohn’s Disease.

Create Possibilities*

HUMIRA and Crohn’s Disease

HUMIRA has been proven to induce and maintain remission (little or no symptoms) in many people with moderate to severe Crohn’s Disease.

Getting out and doing the things you enjoy, instead of focusing on your condition may be possible again with HUMIRA. ^§† If your current Crohn’s Disease treatment isn’t relieving your symptoms, it could be time to consider something new.

What is Crohn’s Disease?

Crohn’s Disease is a chronic relapsing inflammatory bowel disease (IBD). It is characterised by inflammation which can affect any part of the gastrointestinal tract (digestive system).

Find out more about Crohn’s Disease

Find out more

HUMIRA Safety Information

Safety information on this website includes some of the more important information to know about HUMIRA.

How does HUMIRA work?

HUMIRA is a fully human monoclonal antibody. HUMIRA recognises and binds to a specific protein (tumour necrosis factor or TNF-alpha), which is present at increased levels in inflammatory diseases such as Crohn’s Disease.

Taking HUMIRA

What you need to know about taking HUMIRA, including helping you get the best out of your HUMIRA treatment.

Talk with your doctor

We’ve put together a checklist that you can take along to your gastroenterologist visit to discuss symptoms and treatment options.

Download your ‘Getting ready for your gastroenterologist visit’ guide

Download your guide

† All experiences, possible outcomes or improvements are hypothetical and based on significant clinical and Quality Of Life (QOL) improvements as measured in the listed clinical studies following HUMIRA treatment.
*AbbVie medications and programmes are designed to support patients on their health journey.

References:

Ha F & Khalil H. Ther Adv Gastroenterol 2015, Vol. 8(6) 352–359.
HUMIRA (adalimumab) Approved Consumer Medicine information.
HUMIRA (adalimumab) Approved Data Sheet.
Health Navigator Crohn’s Disease https://www.healthnavigator.org.nz/health-a-z/c/crohns-disease/ Accessed November 2019.
Panaccione R, et al. Aliment Pharmacol Ther 2013;1-12.

This site is intended for a New Zealand audience.

Important information about HUMIRA. HUMIRA is a prescription medicine containing adalimumab. HUMIRA is available as a single use pre-filled syringe or single-use pre-filled pen and may contain 20mg, 40mg or 80mg adalimumab. It is used in the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, psoriasis, ulcerative colitis, Crohn’s disease, non-infectious uveitis, and hidradenitis suppurativa. HUMIRA is only used in patients of a specific age group, in diseases of certain severity (e.g. moderate to severe), and/or after some other treatments have been tried (e.g. conventional therapy).

HUMIRA has risks and benefits. Refer to the Safety Information contained on this website for further details. If you have any questions about using HUMIRA, ask your healthcare professional and refer to the Consumer Medicine Information (CMI) available here: HUMIRA PEN CMI or HUMIRA Pre-filled Syringe CMI or by calling freephone 0800 900 030. Ask your doctor if HUMIRA is right for you. Use strictly as directed. If symptoms continue, or you have side effects, see your doctor, pharmacist or healthcare professional.

HUMIRA is a funded prescription medicine under special authorial criteria – for certain indications and patients only. Your doctor can inform you if you are eligible to receive funding. Normal pharmacy and doctor's charge will apply.

AbbVie is the company that brings you HUMIRA (adalimumab). For more information about AbbVie, visit www.AbbVie.co.nz | HUMIRA Data Sheet

AbbVie Limited, 6th floor, 156-158 Victoria street, Wellington, 6011, New Zealand 0800 900 030. HUMIRA and Destination You are registered trademarks of AbbVie Biotechnology Ltd.